These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33096138)

  • 1. Investigating a Modified Apparatus to Discriminate the Dissolution Capacity In Vitro and Establish an IVIVC of Mycophenolate Mofetil Tablets in the Fed State.
    Zhang G; Sun M; Jiang S; Wang L; Tan Y; Wang L; Cheng Z
    J Pharm Sci; 2021 Mar; 110(3):1240-1247. PubMed ID: 33096138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Predictive Dissolution Test Should Be Developed and Recommended as a Bioequivalence Standard for the Immediate-Release Solid Oral Dosage Forms of the Highly Variable Mycophenolate Mofetil.
    Wang K; Li Y; Chen B; Chen H; Smith DE; Sun D; Feng MR; Amidon GL
    Mol Pharm; 2022 Jul; 19(7):2048-2060. PubMed ID: 35603895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
    Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
    Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose, two-way crossover, bioequivalence study of Mycophenolate mofetil 500 mg tablet under fasting conditions in healthy male subjects.
    Patel S; Chauhan V; Mandal J; Shah S; Patel K; Saptarshi D; Maheshwari K; Jha PK; Kale P; Patel K; Mathew P
    Clin Ther; 2011 Mar; 33(3):378-90. PubMed ID: 21600390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Assessment of the in vivo Dissolution Rate to Establish a Modified IVIVC for Isosorbide Mononitrate Tablets.
    Zhang G; Zhang L; Tan Y; Wang L; Cheng Z
    J Pharm Sci; 2023 Jun; 112(6):1705-1714. PubMed ID: 34728173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
    da Silva JD; de Sousa VP; Cabral LM; Davanço MG; Meulman J; de Oliveira Carvalho P; Campos DR
    AAPS PharmSciTech; 2020 Jul; 21(5):195. PubMed ID: 32666354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
    Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
    AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
    Lake OA; Olling M; Barends DM
    Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen.
    Cámara-Martinez I; Blechar JA; Ruiz-Picazo A; Garcia-Arieta A; Calandria C; Merino-Sanjuan V; Langguth P; Gonzalez-Alvarez M; Bermejo M; Al-Gousous J; Gonzalez-Alvarez I
    Int J Pharm; 2022 Feb; 614():121415. PubMed ID: 34973409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Two-Compartment System In vitro Dissolution Test and Correlation with In vivo Pharmacokinetic Studies for Celecoxib.
    Jiang S; Zhang G; Wang L; Zeng Y; Liu W; Cheng Z
    AAPS PharmSciTech; 2020 Jan; 21(2):59. PubMed ID: 31912248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug dissolution and transit in a heterogenous gastric chyme after fed administration: Semi-mechanistic modeling and simulations for an immediate-release and orodispersible tablets containing a poorly soluble drug.
    Danielak D; Gajda M; Bołtromiuk T; Sulikowska K; Kubiak B; Romański M
    Eur J Pharm Biopharm; 2024 Jul; 200():114341. PubMed ID: 38795785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
    Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Dissolution Method for Gliclazide Modified-Release Tablets Using USP Apparatus 3 with in Vitro-in Vivo Correlation.
    Bezerra KC; Pinto EC; Cabral LM; de Sousa VP
    Chem Pharm Bull (Tokyo); 2018; 66(7):701-707. PubMed ID: 29962453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects.
    Almeida S; Filipe A; Neves R; Spínola AC; Tanguay M; Ortuño J; Farré A; Torns A
    Clin Ther; 2010 Mar; 32(3):556-74. PubMed ID: 20399993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
    Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
    Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.
    González-García I; García-Arieta A; Merino-Sanjuan M; Mangas-Sanjuan V; Bermejo M
    Eur J Pharm Sci; 2018 Jul; 119():200-207. PubMed ID: 29680456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
    Lim JY; Kim TH; Song CH; Kim DH; Shin BS; Shin S
    J Control Release; 2022 Mar; 343():443-456. PubMed ID: 35124130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.